Completed PHASE3 INTERVENTIONAL NCT00370565

Effect on Glycemic Control of Inhaled Insulin Alone or Added to Dual Oral Therapy After Failure of Dual Oral Therapy.

Efficacy And Safety Of Exubera (Inhaled Insulin) Therapy In Subjects With Type 2 Diabetes Mellitus Not Well Controlled With Combination Oral Agents: A Three-Month, Outpatient, Parallel Comparative Trial.

Sponsor: Nektar Therapeutics

Conditions Diabetes Mellitus, Type 2

Interventions Inhaled Human Insulin

Updated 7 times since 2017 Last updated: Feb 9, 2007 Started: Jun 30, 1999 Completion: Sep 30, 2000

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00370565, this PHASE3 trial focuses on Diabetes Mellitus, Type 2 and remains completed. Sponsored by Nektar Therapeutics, it has been updated 7 times since 1999, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed PHASE3
Sep 2025 — Present [monthly]

Completed PHASE3
Sep 2024 — Sep 2025 [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Jun 1999

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Nektar Therapeutics
Pfizer
Sanofi

Data source: Pfizer

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Austin, United States , Burlington, United States , Calgary, Canada , Clearwater, United States , Cleveland, United States , Columbia, United States , Dallas, United States , Edmonton, Canada , Greenville, United States , Halifax, Canada and 31 more locations